Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Roger Esteban-FabróCatherine E WilloughbyMarta Piqué-GiliCarla MontironiJordi Abril-FornagueraJudit PeixLaura TorrensAgavni MesropianUgne BalaseviciuteFrancesc Miró-MurVincenzo MazzaferroRoser PinyolJosep M LlovetPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Cabozantinib in combination with anti-PD1 enhanced antitumor immunity by bringing together innate neutrophil-driven and adaptive immune responses, a mechanism of action which favors this approach for HCC treatment.